🟢 Insulet Corporation is trading 5.2% up today on Omnipod 5 enhancements and Abbott sensor integration

Insulet Corporation is trading 5.2% up at $153.99 following the U.S. rollout of significant enhancements to its Omnipod 5 automated insulin delivery system.

• The update introduces a lower 100 mg/dL glucose target and new compatibility with Abbott’s FreeStyle Libre 3 Plus sensor.
• Investors view the integration as a meaningful product and ecosystem upgrade expected to support stronger adoption and future growth.